T-cell immunodeficiency following cytotoxic antineoplastic therapy: A review

Crystal L. Mackall

Research output: Contribution to journalArticle

Abstract

Although cancer itself is immunosuppressive, cytotoxic antineoplastic therapy is the primary contributor to the clinical immunodeficiency observed in cancer patients. The immunodeficiency induced by cytotoxic antineoplastic therapy is primarily related to T-cell depletion, with CD4 depletion generally more severe than CD8 depletion. Myeloablative therapy, dose- intensive alkylating agents, purine nucleoside analogs, and corticosteroids substantially increase the risk of therapy-induced immunosuppression. Restoration of T-cell populations following cytotoxic antineoplastic therapy is a complex process. Efficient recovery of CD4+ T cell populations requires thymic-dependent pathways which undergo an age-dependent decline resulting in prolonged CD4+ T-cell depletion in adults following T-cell-depleting therapy. Total CD8+ T-cell numbers recover in both children and adults relatively quickly post-therapy; however, CD8+ subset disruptions often remain for a prolonged period. The clinical management of patients with therapy-induced T-cell depletion involves the maintenance of a high index of suspicion for opportunistic pathogens, irradiation of blood products, prophylaxis for viral infectious, and reimmunization in selected clinical circumstances. Future research avenues include efforts to rapidly rebuild immunity following cytotoxic antineoplastic therapy so that immune-based therapies may be utilized immediately following cytotoxic therapy to target minimal residual neoplastic disease.

Original languageEnglish (US)
Pages (from-to)10-18
Number of pages9
JournalStem Cells
Volume18
Issue number1
StatePublished - 2000
Externally publishedYes

Fingerprint

Antineoplastic Agents
T-Lymphocytes
Therapeutics
Purine Nucleosides
Alkylating Agents
Residual Neoplasm
Immunosuppressive Agents
Cell- and Tissue-Based Therapy
Immunosuppression
Population
Immunity
Neoplasms
Adrenal Cortex Hormones
Cell Count

Keywords

  • Immune reconstitution
  • Immunodeficiency
  • T cells
  • Thymus

ASJC Scopus subject areas

  • Cell Biology

Cite this

T-cell immunodeficiency following cytotoxic antineoplastic therapy : A review. / Mackall, Crystal L.

In: Stem Cells, Vol. 18, No. 1, 2000, p. 10-18.

Research output: Contribution to journalArticle

Mackall, Crystal L. / T-cell immunodeficiency following cytotoxic antineoplastic therapy : A review. In: Stem Cells. 2000 ; Vol. 18, No. 1. pp. 10-18.
@article{94065e5efca145ea807de2909be83152,
title = "T-cell immunodeficiency following cytotoxic antineoplastic therapy: A review",
abstract = "Although cancer itself is immunosuppressive, cytotoxic antineoplastic therapy is the primary contributor to the clinical immunodeficiency observed in cancer patients. The immunodeficiency induced by cytotoxic antineoplastic therapy is primarily related to T-cell depletion, with CD4 depletion generally more severe than CD8 depletion. Myeloablative therapy, dose- intensive alkylating agents, purine nucleoside analogs, and corticosteroids substantially increase the risk of therapy-induced immunosuppression. Restoration of T-cell populations following cytotoxic antineoplastic therapy is a complex process. Efficient recovery of CD4+ T cell populations requires thymic-dependent pathways which undergo an age-dependent decline resulting in prolonged CD4+ T-cell depletion in adults following T-cell-depleting therapy. Total CD8+ T-cell numbers recover in both children and adults relatively quickly post-therapy; however, CD8+ subset disruptions often remain for a prolonged period. The clinical management of patients with therapy-induced T-cell depletion involves the maintenance of a high index of suspicion for opportunistic pathogens, irradiation of blood products, prophylaxis for viral infectious, and reimmunization in selected clinical circumstances. Future research avenues include efforts to rapidly rebuild immunity following cytotoxic antineoplastic therapy so that immune-based therapies may be utilized immediately following cytotoxic therapy to target minimal residual neoplastic disease.",
keywords = "Immune reconstitution, Immunodeficiency, T cells, Thymus",
author = "Mackall, {Crystal L.}",
year = "2000",
language = "English (US)",
volume = "18",
pages = "10--18",
journal = "Stem Cells",
issn = "1066-5099",
publisher = "AlphaMed Press",
number = "1",

}

TY - JOUR

T1 - T-cell immunodeficiency following cytotoxic antineoplastic therapy

T2 - A review

AU - Mackall, Crystal L.

PY - 2000

Y1 - 2000

N2 - Although cancer itself is immunosuppressive, cytotoxic antineoplastic therapy is the primary contributor to the clinical immunodeficiency observed in cancer patients. The immunodeficiency induced by cytotoxic antineoplastic therapy is primarily related to T-cell depletion, with CD4 depletion generally more severe than CD8 depletion. Myeloablative therapy, dose- intensive alkylating agents, purine nucleoside analogs, and corticosteroids substantially increase the risk of therapy-induced immunosuppression. Restoration of T-cell populations following cytotoxic antineoplastic therapy is a complex process. Efficient recovery of CD4+ T cell populations requires thymic-dependent pathways which undergo an age-dependent decline resulting in prolonged CD4+ T-cell depletion in adults following T-cell-depleting therapy. Total CD8+ T-cell numbers recover in both children and adults relatively quickly post-therapy; however, CD8+ subset disruptions often remain for a prolonged period. The clinical management of patients with therapy-induced T-cell depletion involves the maintenance of a high index of suspicion for opportunistic pathogens, irradiation of blood products, prophylaxis for viral infectious, and reimmunization in selected clinical circumstances. Future research avenues include efforts to rapidly rebuild immunity following cytotoxic antineoplastic therapy so that immune-based therapies may be utilized immediately following cytotoxic therapy to target minimal residual neoplastic disease.

AB - Although cancer itself is immunosuppressive, cytotoxic antineoplastic therapy is the primary contributor to the clinical immunodeficiency observed in cancer patients. The immunodeficiency induced by cytotoxic antineoplastic therapy is primarily related to T-cell depletion, with CD4 depletion generally more severe than CD8 depletion. Myeloablative therapy, dose- intensive alkylating agents, purine nucleoside analogs, and corticosteroids substantially increase the risk of therapy-induced immunosuppression. Restoration of T-cell populations following cytotoxic antineoplastic therapy is a complex process. Efficient recovery of CD4+ T cell populations requires thymic-dependent pathways which undergo an age-dependent decline resulting in prolonged CD4+ T-cell depletion in adults following T-cell-depleting therapy. Total CD8+ T-cell numbers recover in both children and adults relatively quickly post-therapy; however, CD8+ subset disruptions often remain for a prolonged period. The clinical management of patients with therapy-induced T-cell depletion involves the maintenance of a high index of suspicion for opportunistic pathogens, irradiation of blood products, prophylaxis for viral infectious, and reimmunization in selected clinical circumstances. Future research avenues include efforts to rapidly rebuild immunity following cytotoxic antineoplastic therapy so that immune-based therapies may be utilized immediately following cytotoxic therapy to target minimal residual neoplastic disease.

KW - Immune reconstitution

KW - Immunodeficiency

KW - T cells

KW - Thymus

UR - http://www.scopus.com/inward/record.url?scp=0033969247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033969247&partnerID=8YFLogxK

M3 - Article

C2 - 10661568

AN - SCOPUS:0033969247

VL - 18

SP - 10

EP - 18

JO - Stem Cells

JF - Stem Cells

SN - 1066-5099

IS - 1

ER -